HLB Therapeutics Co.,Ltd. (115450.KQ)
KRW 10680.0
(-2.11%)
KRW 10680.0
(-2.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -13.68 Billion KRW | -316.92% |
| 2022 | 6.3 Billion KRW | 112.94% |
| 2021 | -48.74 Billion KRW | -8077.21% |
| 2020 | -596.12 Million KRW | -110.7% |
| 2019 | 5.57 Billion KRW | 171.41% |
| 2018 | -7.8 Billion KRW | -189.5% |
| 2017 | 8.71 Billion KRW | 45.29% |
| 2016 | 5.99 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 8.93 Billion KRW | 193.85% |
| 2024 Q1 | -9.51 Billion KRW | 30.48% |
| 2023 Q1 | 5.21 Billion KRW | -17.36% |
| 2023 Q4 | -13.68 Billion KRW | -204.22% |
| 2023 Q3 | 13.13 Billion KRW | 262.21% |
| 2023 Q2 | 3.62 Billion KRW | -30.47% |
| 2023 FY | -13.68 Billion KRW | -316.92% |
| 2022 Q3 | 856.39 Million KRW | -18.41% |
| 2022 Q4 | 6.3 Billion KRW | 636.76% |
| 2022 Q1 | 30.98 Billion KRW | 163.57% |
| 2022 Q2 | 1.04 Billion KRW | -96.61% |
| 2021 Q3 | -8.89 Billion KRW | 0.0% |
| 2021 Q4 | -48.74 Billion KRW | -448.15% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 70.364% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 66.276% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 130.182% |
| Bioneer Corporation | -3.9 Billion KRW | -250.243% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 263.878% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 192.389% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 252.212% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 43.966% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 103.519% |
| Medy-Tox Inc. | 49.58 Billion KRW | 127.603% |
| Peptron, Inc. | 4.86 Billion KRW | 381.122% |
| Amicogen, Inc. | 125.26 Billion KRW | 110.926% |
| Genexine, Inc. | 61.39 Billion KRW | 122.293% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 75.583% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 125.549% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 58.447% |
| SillaJen, Inc. | -13.89 Billion KRW | 1.474% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 116.24% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 149.998% |
| Genomictree Inc. | -43.43 Billion KRW | 68.489% |
| MedPacto, Inc. | -64 Billion KRW | 78.615% |
| D&D Pharmatech | -7.5 Billion KRW | -82.301% |
| EASY BIO,Inc. | 53.21 Billion KRW | 125.722% |
| GI Innovation, Inc. | -4.82 Billion KRW | -183.81% |